Forget small-caps! I think FTSE 100 pharma investors will profit most from coronavirus tests

first_img Our 6 ‘Best Buys Now’ Shares I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. Tom Rodgers | Friday, 24th April, 2020 See all posts by Tom Rodgers “This Stock Could Be Like Buying Amazon in 1997” Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. I believe FTSE 100 pharmaceutical heavyweights AstraZeneca and GlaxoSmithKline will be the biggest winners from the rapid increase in UK coronavirus testing.Why do I say that? Let me point you to Sir Kier Starmer’s first appearance as Labour leader at Prime Minister’s Questions. It was generally regarded as a solid debut. The former director of public prosecutions tore into First Secretary Dominic Raab for the government’s lack of activity to increase coronavirus immunity testing.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…The Department of Health target is 100,000 tests per day by the end of April 2020. However, it has a capacity of only 40,000 tests per day, Raab said. Furthermore, fewer than 20,000 tests per day are being carried out each day at present.Whatever your political leaning, we can all agree that analysis of workers’ Covid-19 immunity will be vital for reopening the shuttered UK economy.Starmer’s line of questioning teased out some interesting detail from Raab. He highlighted that AZN and GSK are setting up the next major Covid-19 testing laboratory at Cambridge University. This news has broad financial implications for the two FTSE 100 companies.FTSE 100 FTWCoronavirus testing has become something of a gold rush in the UK. Several small AIM-listed companies are investing heavily in new biotech projects. And investors thick with cash are piling in to relative unknowns on promise alone.Shares in the Anglo-French firm Novacyt, for example, are up 2,750% since the start of 2020. But I contend that FTSE 100 pharma giants are much more likely to improve their earnings with large government contracts.AstraZeneca and GlaxoSmithKline’s new laboratory at Cambridge University is “for high throughput screening of Covid-19 testing”, says a press release. It will “explore the use of alternative chemical reagents for test kits in order to help overcome current supply shortages“.Even if life sciences minnows wanted to, they could not achieve the necessary processes fast enough to command the scale that governments require.Only the FTSE 100 pharma giants have the industry contacts, economies of scale, and supply chain depth to produce the required millions of tests per month.This is why UK government contracts tend to go to the same players all the time. That includes Capita for IT or G4S for security. No matter that these examples are often heavily criticised for their evident shortcomings.Dividend certaintyThere is also the question of dividends. Yes, an investment in Novacyt or its AIM-listed alternatives may produce some short-term capital gains. But no dividends. And small-cap prices are also prone to extreme volatility.By contrast, my two picks are defensive choices that have rapidly bounced back from the market bottom on 19 March 2020.In addition, we are witnessing wide-scale FTSE 100 dividend suspension. In the worst case scenario, the index’s average yield will fall from 4.35% in 2019 to just 2% in 2020.GSK is widely regarded as one of the safest dividend payouts on the FTSE 100. For example, CEO Emma Walmsley doles out a 5% yield per share every year like clockwork. AstraZeneca pays out $2.80 per share annually without fail. Dependable is best. This is where I, and the government, can place our faith for the future. I’m sure you’ll agree that’s quite the statement from Motley Fool Co-Founder Tom Gardner.But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.What’s more, we firmly believe there’s still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.And right now, we’re giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.center_img Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge! Forget small-caps! I think FTSE 100 pharma investors will profit most from coronavirus tests Image source: Getty Images Enter Your Email Address Tom Rodgers owns shares in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Simply click below to discover how you can take advantage of this.last_img read more

One killed in two-vehicle crash

first_img Twitter Local News Twitter WhatsApp View of an evidence vault in the Ector County Courthouse jail that was used for the U.S. Marshal’s Service. The jail and offices took up approximately 45,000 square feet. One man was killed and an Odessa man was injured in a two-vehicle crash Wednesday in Glasscock County.Highway troopers responded to the crash around 8:07 p.m. Wednesday near State Highways 158 and 137, 14 miles west of Garden City, a Texas Department of Public Safety news release stated.The release detailed that 29-year-old Johnny Reyna of Edcouch was driving east in a 1999 Kenworth truck tractor towing a semi-trailer and approaching a traffic light at the intersection of SH 148 and SH 137. Maman Muchtarman, 49, of Odessa was driving north on SH 137 in a 2014 Peterbilt truck tractor with 22-year-old Christian Enriquez-Rodriguez of Hidalgo.Reyna reportedly disregarded the red light at the intersection and collided with Muchtarman’s vehicle, the release stated.A justice of the peace pronounced Reyna dead at the scene, the release detailed. Muchtarman was taken to Medical Center Hospital with incapacitating injuries and Enriquez-Rodriguez as taken to Midland Memorial Hospital with non-incapacitating injuries.The release detailed that Reyna was not wearing his seatbelt at the time, and it is unknown if the other two were wearing seatbelts. Pinterest Pinterest Facebook Previous articleHIGH SCHOOL TENNIS: Wink’s Jonnah Smith qualifies for state in two sportsNext articleDAILY OIL PRICE: May 10 admin WhatsApp By admin – May 10, 2018 One killed in two-vehicle crash Facebooklast_img read more

Brian Boyle steps down from Tipp Camogie side

first_imgBrian says it was a tough decision to call it a day.730 Brian Boyle[CLIP] Tipperary Senior Camogie Manager Brian Boyle says the team is capable of great things in the future.The Drom & Inch man was speaking after stepping down from a seven year term with the Tipp camogie set-up.Tipp lost out to Galway in the recent All Ireland quarter-final. [mixcloud https://www.mixcloud.com/TippFM/boyle/ width=100% height=60 hide_cover=1 mini=1 light=1]last_img